^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CMPK1 (Cytidine/Uridine Monophosphate Kinase 1)

    i
    Other names: CMPK1, Cytidine/Uridine Monophosphate Kinase 1, UMP-CMP Kinase, UMP/CMP Kinase, UMP-CMPK, CMPK, Cytidine Monophosphate (UMP-CMP) Kinase 1 Cytosolic, Uridine Monophosphate/Cytidine Monophosphate Kinase, Nucleoside-Diphosphate Kinase, Deoxycytidylate Kinase, Cytidylate Kinase, DCMP Kinase, UMPK, CMK, UMK, CK, Cytidine Monophosphate Kinase, Uridine Monophosphate Kinase, UMP/CMPK, UCK
    Associations

    News

    Trials
    7ms
    The Impact of the Rs1044457 Polymorphism in the CMPK1 Gene on the Response Rate to Gemcitabine-Based Chemotherapy in Metastatic NSCLC Patients. (PubMed, Adv Genet (Hoboken))
    Additionally, at the allelic level, the mutant allele (T) is more common in non-responder patients (36.46%) compared to responder patients (23%), with a statistically significant odds ratio of 1.92 (95% CI = 1.03-3.58, p = 0.040). The findings of this study suggest that the mutant allele (allele T) of the rs1044457 variant may serve as a risk factor for resistance to gemcitabine-based chemotherapy in patients with NSCLC.
    Journal
    |
    CMPK1 (Cytidine/Uridine Monophosphate Kinase 1)
    |
    gemcitabine
    over1year
    Exosomal miRNA 16-5p/29a-3p from pancreatic cancer induce adipose atrophy by inhibiting adipogenesis and promoting lipolysis. (PubMed, iScience)
    Thus, we unravel that PDAC induces adipose atrophy via exosomal miRs. This knowledge may provide new diagnostic and therapeutic strategies for PDAC-induced cachexia.
    Journal
    |
    MIR21 (MicroRNA 21) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • SLC16A1 (Solute Carrier Family 16 Member 1) • MIR16 (MicroRNA 16) • CMPK1 (Cytidine/Uridine Monophosphate Kinase 1) • MIR29A (MicroRNA 29a)
    over4years
    Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11). (PubMed, ESMO Open)
    Genetic polymorphisms of rs1044457 in CMPK1, rs693955 in SLC29A1, and rs2807312 in TLE4 were significantly associated with the 6-month PFS rate and/or the duration of PFS. Further studies with a larger sample size and expression study would be helpful to validate the association of genetic polymorphisms and clinical efficacy of gemcitabine.
    Clinical • P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • SLC29A1 (Solute Carrier Family 29 Member 1) • CMPK1 (Cytidine/Uridine Monophosphate Kinase 1) • TLE4 (TLE Family Member 4 Transcriptional Corepressor)
    |
    HER-2 negative
    |
    gemcitabine • paclitaxel • Halaven (eribulin mesylate)